281. Correction to: Abstract 4368321: A Rare Unusual Location Of A Papillary Fibroelastoma Originating From The Coumadin Ridge.
作者: Joud Fahed.;Wongelawit Zerihun.;Danhue Moodie.;Kaushal Sigdel.;Matthew Voss.;Jesse Doran.
来源: Circulation. 2026年153卷21期e1360-e1361页 284. Impact of Angina on Outcome After Percutaneous Coronary Intervention in Patients Undergoing Transcatheter Aortic Valve Implantation: Insights From the NOTION-3 Trial.
作者: Casper Ferreira Zimmer.;Jasmine Melissa Marquard.;Reza Jabbari.;Muhammad Sabbah.;Charlotte Glinge.;Karsten Tange Veien.;Matti Niemelä.;Phillip Freeman.;Rickard Linder.;Rikke Sørensen.;Lene Holmvang.;Dan Ioanes.;Christian Juhl Terkelsen.;Julia Ellert-Gregersen.;Evald Christiansen.;Ashkan Eftekhari.;Jarkko Piuhola.;Olli Kajander.;Sasha Koul.;Mikko Savontaus.;Pasi Karjalainen.;Andreas Rück.;Oskar Angerås.;Gintautas Bieliauskas.;Troels Højsgaard Jørgensen.;Lars Søndergaard.;Ole De Backer.;Thomas Engstrøm.;Jacob Lønborg.
来源: Circulation. 2026年153卷21期1687-1690页 286. Response by Croon and Khera to Letter Regarding Article, "Phenotypic Selectivity of Artificial Intelligence-Enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction".287. Hypoxia Upregulation of BACH1 Aggravates Pulmonary Hypertension Through TGFBR2/SMAD Pathways.
作者: Yannan Hou.;Qinhan Li.;Tong-You Wade Wei.;Xiaoke Lin.;Jieyu Guo.;Ping Yuan.;Hui Shen.;Ya Gao.;Qi Pan.;Chen Xu.;Valentina Biasin.;Yongbo Li.;Yunquan He.;Jian Wu.;Liliang Li.;Jiayu Jin.;Xiangxiang Wei.;Jiayi Lin.;Siyu Ma.;Nan Jiang.;Jinghua Ma.;Xiuling Zhi.;Qingjun Jiang.;Lefeng Qu.;Qianqian Liang.;Lindi Jiang.;Elena Osto.;John Y-J Shyy.;Xinhong Wang.;Dan Meng.
来源: Circulation. 2026年154卷2期117-135页
Vascular remodeling is a central characteristic of pulmonary hypertension (PH), yet the precise mechanisms underlying this process remain poorly understood.
288. Pulsed Field Ablation Versus Sham to Treat Atrial Fibrillation: The PFA-SHAM Randomized Clinical Trial.
作者: Pavel Osmancik.;Petr Neuzil.;Jana Hozmanova.;Jan Petru.;Dalibor Herman.;Stepan Kralovec.;Marek Hozman.;Marko Tichy.;Petr Waldauf.;Tomas Karel.;Lucie Sediva.;Jakub Fischer.;Lubomir Stepanek.;Ivana Mala.;Veronika Lekesova.;Pavel Hala.;Moritoshi Funasako.;Jana Vesela.;Vera Filipcova.;Jakub Karch.;William Whang.;Vivek Y Reddy.
来源: Circulation. 2026年153卷25期1984-1998页
Catheter ablation for atrial fibrillation (AF) is one of the most common cardiovascular procedures being performed worldwide. Despite the large body of evidence of its effectiveness, with a single exception, prior ablation studies were largely unblinded trials. Accordingly, residual concerns remained about placebo effects, both for AF recurrence and, in particular, on subjective outcomes such as quality of life or anxiety. Here, we compared pulsed field ablation (PFA) with a sham procedure to treat patients with symptomatic AF.
290. Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial.
作者: Victorien Monguillon.;Nicholas A Marston.;Erin A Bohula.;Jeong-Gun Park.;Julia F Kuder.;Sabina A Murphy.;Gaetano M De Ferrari.;Lawrence A Leiter.;Jose C Nicolau.;Christoph Ebenbichler.;Peter Sinnaeve.;Assen Goudev.;Andrzej Budaj.;Oleg Averkov.;Lale Tokgözoğlu.;Ron Blankstein.;Dragos Vinereanu.;Robert P Giugliano.;Marc S Sabatine.;Michelle L O'Donoghue.
来源: Circulation. 2026年153卷25期1960-1968页
Lp(a) (lipoprotein[a]) is a risk factor for coronary heart disease. Whether baseline Lp(a) identifies higher-risk patients who derive more benefit from evolocumab is not established in a population without previous myocardial infarction (MI) or stroke.
291. SREBP1 Transactivation of NHE3 Impairs Cardiac Contraction and Aggravates Heart Failure.
作者: Huijun Gu.;Jianpei Wen.;Yiyi Liu.;Yanbo Xue.;Mingming Zhao.;Yifei Zhao.;Lantian Bi.;Hongtu Cui.;Wenming Zhang.;Wenli Xu.;Kang Wang.;Yawen Deng.;Xiaoyue Yu.;Haifan Wang.;Jingui Hu.;Wei Liu.;Yuxuan Guo.;Chen Chen.;Erdan Dong.;Youyi Zhang.;John Y-J Shyy.;Han Xiao.
来源: Circulation. 2026年154卷5期474-489页
Heart failure with reduced ejection fraction (HFrEF) is characterized by impaired contractility and high mortality. Dysregulation of intracellular ion (ie, Na+/H+ and Ca2+) cycling underlies reduced cardiac contractility. The mechanisms linking myocardial stress to this ion dysregulation remain incompletely understood. Although the metabolic transcription factor SREBP1 (sterol regulatory element-binding protein 1) remodels cardiac metabolism, its role in HFrEF without metabolic comorbidities, particularly regarding ion handling, remains undefined.
292. Sam68 Exacerbates Pathologic Cardiac Hypertrophy by Suppressing Cardiomyocyte Glucose Oxidation.
作者: Junqing An.;Chaoshan Han.;Ying Jiang.;Jiawei Shi.;Huadong Li.;Chenqi Wang.;Jianrong Huang.;Shiyue Xu.;Jie Ni.;Yangpo Cao.;Yuliang Feng.;Qing Lyu.;Nianguo Dong.;Gangjian Qin.
来源: Circulation. 2026年153卷25期2044-2063页
Metabolic remodeling, marked by maladaptive shifts in substrate use and energy production, is a hallmark of pathologic cardiac hypertrophy. Yet the mechanisms linking stress signaling to impaired myocardial glucose oxidation remain incompletely defined. Sam68 (Src-associated in mitosis, 68 kDa; also known as KHDRBS1 [KH domain-containing, RNA-binding, signal transduction-associated protein 1]), a STAR (signal transduction and activation of RNA) family RNA-binding protein, has not previously been implicated in cardiac metabolic control.
293. Prognostic Impact of LGE Granularity Using CMR in End‑Stage Hypertrophic Cardiomyopathy.
作者: Julien Hudelo.;Jérôme Garot.;Solenn Toupin.;Suzanne Duhamel.;Francesca Sanguineti.;Philippe Garot.;Thomas Hovasse.;Stéphane Champagne.;Thierry Unterseeh.;Mariama Akodad.;Antoinette Neylon.;Trecy Gonçalves.;Alexandre Unger.;Jeremy Florence.;Jean-Guillaume Dillinger.;Christophe Tribouilloy.;Alexis Hermida.;Valérie Bousson.;Théo Pezel.;Yohann Bohbot.
来源: Circ Cardiovasc Imaging. 2026年19卷6期e019408页
End-stage hypertrophic cardiomyopathy (HCM) is a distinct and advanced form of HCM, defined by a left ventricular ejection fraction <50% and associated with a markedly poor prognosis. Evidence on the prognostic relevance of late gadolinium enhancement (LGE) and its key features in end-stage HCM remains limited. The aim of our study was to evaluate the prognostic value of the LGE granularity model, including its location, extent, and pattern in patients with end-stage HCM.
295. Adolescent Cardiorespiratory Fitness and the Trade-Off Between Atrial Fibrillation Risk and Cardiovascular Benefits: A Nationwide Sibling-Controlled Cohort Study.
作者: Marcel Ballin.;Axel C Carlsson.;Per Wändell.;Viktor H Ahlqvist.;Mattias Brunström.;Pontus Henriksson.;Anna Nordström.;Peter Nordström.
来源: Circulation. 2026年154卷1期7-15页
Young athletes and adolescents with high cardiorespiratory fitness appear to have a higher risk of atrial fibrillation (AF), but the extent to which this reflects causal effects or shared genetic, behavioral, and environmental factors remains uncertain.
296. Cardiac Intensive Care Unit Appropriate Patient Selection and Triage: A Scientific Statement From the American Heart Association.
作者: Sean van Diepen.;Penelope Rampersad.;Adriana Luk.;Garima Dahiya.;Emily K Zern.;Carlos L Alviar.;Christopher F Barnett.;Erin A Bohula.;Jason A Bartos.;Tammy M Slater.;Guido Tavazzi.;Ann Gage.; .; .; .; .
来源: Circulation. 2026年153卷23期e1394-e1407页
Cardiac intensive care units are specialized, high-acuity, and resource-intensive environments for the care of critically ill patients with cardiovascular disease. Over the past 60 years, medical and interventional therapeutic advances have improved survival and reduced the risk of life-threatening arrythmias in many common cardiovascular conditions. Nonetheless, some hospitals have maintained historical cardiac intensive care admission practices, resulting in admissions of low-acuity patients who could otherwise be cared for in a telemetry-equipped hospital ward environment. These triage practices may be partially attributable to a lack of guidance from international societies on contemporary cardiac intensive care admission standards. In this scientific statement, we propose cardiac intensive care triage practice standards for common cardiovascular conditions, summarize available prediction scores, and outline priorities for future health services research in this field.
297. Direct Oral Anticoagulant Monotherapy Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: A Meta-Analysis of Randomized Trials.
作者: Nicola Ammirabile.;Daniele Giacoppo.;Placido Maria Mazzone.;Davide Landolina.;Davide Capodanno.
来源: Circ Cardiovasc Interv. 2026年19卷6期e016554页 298. Impact of Intravascular Imaging on Clinical Outcomes in Focal Versus Diffuse Coronary Artery Disease.
作者: Taito Arai.;Koshiro Sakai.;Kazumasa Ikeda.;Takuya Mizukami.;Frédéric Bouisset.;Han Zhang.;Mitsuaki Matsumura.;Jeroen Sonck.;Adriaan Wilgenhof.;Hitoshi Matsuo.;Tetsuya Amano.;Hirohiko Ando.;Masahiro Hada.;Brian Ko.;Simone Biscaglia.;Fernando Rivero.;Thomas Engstrøm.;Antonio Maria Leone.;Lokien X van Nunen.;William F Fearon.;Evald Høj Christiansen.;Stephane Fournier.;Liyew Desta.;Andy Yong.;Julien Adjedj.;Javier Escaned.;Masafumi Nakayama.;Ashkan Eftekhari.;Danielle Keulards.;Frederik M Zimmermann.;Ethan Korngold.;Daniel Munhoz.;Gianluca Campo.;Colin Berry.;Damien Collison.;Thomas W Johnson.;Divaka Perera.;Allen Jeremias.;Ziad Ali.;Bernard De Bruyne.;Gary S Mintz.;Nils Johnson.;Toshiro Shinke.;Carlos Collet.
来源: Circ Cardiovasc Interv. 2026年e016735页
Intravascular imaging (IVI) during percutaneous coronary intervention (PCI) improves outcomes. Pullback pressure gradient characterizes coronary artery disease patterns as focal or diffuse; however, the benefit of IVI across this spectrum remains incompletely understood. We aimed to evaluate clinical outcomes after PCI with or without IVI guidance in patients with focal and diffuse disease defined by pullback pressure gradient.
299. One-Year Outcomes of the First 1000 Patients Implanted With the Medtronic Micra AV Leadless Pacing System in France: The AV-CESAR Cohort Study.
作者: Fawzi Kerkouri.;Nicolas Clementy.;Pascal Defaye.;Mina Ait Said.;Antoine Andorin.;Frédéric Anselme.;Warda Aoudjeghout.;Marc Badoz.;Nathalie Behar.;Nazih Benhenda.;Mouna Ben Kilani.;Alexandre Bodin.;Pierre Bordachar.;Abdeslam Bouzeman.;Olivier Citerne.;Jean-Claude Deharo.;Carine Dommerc.;Mathieu Echivard.;Fabrice Extramiana.;Laurent Fauchier.;Rodrigue Garcia.;Edouard Gitenay.;Charles Guenancia.;Benoît Guy-Moyat.;Peggy Jacon.;Laurence Jesel.;Christophe Juin.;Ziad Khoueiry.;Maciej Kubala.;Christophe Leclercq.;Vincent Mansourati.;Christelle Marquié.;Alexis Mechulan.;Pierre Mondoly.;Kumar Narayanan.;Pierre Ollitrault.;Jean-Luc Pasquié.;Angelique Peret.;Hervé Poty.;Frederic Sebag.;Olivier Villejoubert.;Xavier Waintraub.;Victor Waldmann.;Serge Boveda.;Jacques Mansourati.;Eloi Marijon.; .
来源: Circ Arrhythm Electrophysiol. 2026年19卷6期e014850页
Evidence supporting the Micra AV leadless pacing system has largely derived from highly experienced centers, potentially limiting generalizability to routine clinical practice.
300. Safety and Outcomes of Intracardiac Versus Transesophageal Echocardiography for Left Atrial Appendage Closure in the Very Elderly: Propensity Score Matched Real-World Outcomes From a Large US Network.
作者: Khalid Sawalha.;Saeed Abughazaleh.;Kyle Gobeil.;Marshal Fox.;Guy Rozen.;E Kevin Heist.;Fadi Chalhoub.
来源: Circ Arrhythm Electrophysiol. 2026年19卷6期e014864页
Intracardiac echocardiography (ICE) is increasingly used to guide left atrial appendage occlusion as an alternative to transesophageal echocardiography (TEE), particularly in elderly patients for whom general anesthesia may pose additional risks. Real-world comparative safety data in older adults remain limited, with prior studies including only small ICE cohorts. We aimed to compare short- and long-term outcomes of ICE- versus TEE-guided left atrial appendage occlusion in adults aged ≥80 years.
|